Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00064779 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00076986 | The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 3 | 300 | INSYS Therapeutics IncINDUSTRY | 6 | Jun 6, 2011 | clinicaltrials |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | terminated | Phase 2 | 30 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 231 | NovartisINDUSTRY | 1 | May 16, 2011 | clinicaltrials |
| NCT00154375 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | completed | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00686387 | Establishment of a Brain and Spinal Tumor Tissue Bank | unknown | — | 70 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 12, 2011 | clinicaltrials |
| NCT01181193 | Vitamin D for Treatment of Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 20 | Soroka University Medical CenterOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT00635557 | Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 30 | Myrexis Inc.INDUSTRY | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01317888 | Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas | unknown | N/A | 11 | Drexel UniversityOTHER | 0 | Mar 17, 2011 | clinicaltrials |
| NCT01308632 | Metronomic Temozolamide in Patients With Recurrent Glioblastoma | unknown | Phase 2 / Phase 3 | 30 | Grupo Español de Investigación en NeurooncologíaOTHER | 0 | Mar 4, 2011 | clinicaltrials |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy(Glass-Art) | terminated | Phase 3 | 9 | Bradmer Pharmaceuticals Inc.INDUSTRY | 0 | Feb 10, 2011 | clinicaltrials |
| NCT00238797 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | completed | Phase 2 | 36 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT01242566 | Temozolomide in Elderly Patients With KPS < 70(TAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 17, 2010 | clinicaltrials |
| NCT00562419 | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | unknown | Phase 2 | 72 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT00768911 | CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 1 | 30 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT01208909 | Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI) | unknown | — | 40 | University of ZurichOTHER | 1 | Oct 22, 2010 | clinicaltrials |
| NCT00535379 | SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme(SURGE01-07) | unknown | Phase 2 | 70 | Medical University InnsbruckOTHER | 2 | Aug 30, 2010 | clinicaltrials |
| NCT00643825 | Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients(PATSGO) | unknown | Phase 2 | 64 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jul 23, 2010 | clinicaltrials |
| NCT00936052 | Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma(HBO) | unknown | Phase 2 | 20 | Neurological Surgery, P.C.OTHER | 1 | Jul 16, 2010 | clinicaltrials |
| NCT00800917 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 12 | Rigshospitalet, DenmarkOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT01083719 | A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes. | unknown | Phase 2 | 15 | Medanta Institute of Clinical ResearchOTHER | 0 | Mar 10, 2010 | clinicaltrials |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | withdrawn | Phase 2 | 5 | National Taiwan University HospitalOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | terminated | Phase 2 | 40 | Thallion PharmaceuticalsINDUSTRY | 2 | Dec 30, 2009 | clinicaltrials |
| NCT00503204 | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | completed | Phase 1 | 20 | AstraZenecaINDUSTRY | 2 | Nov 25, 2009 | clinicaltrials |
| NCT00224978 | Chloroquine for Treatment of Glioblastoma Multiforme | completed | Phase 3 | — | National Institute of Neurology and Neurosurgery, MexicoOTHER | 1 | Nov 18, 2009 | clinicaltrials |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 3 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | terminated | Phase 2 | 40 | Methodist Healthcare - MemphisOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00944801 | Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 63 | University of RegensburgOTHER | 1 | Jul 23, 2009 | clinicaltrials |
| NCT00591058 | Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 | 36 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00683761 | A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | unknown | Phase 1 / Phase 2 | 64 | TransMolecularINDUSTRY | 1 | Jul 17, 2009 | clinicaltrials |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme | withdrawn | Phase 1 | 30 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | May 20, 2009 | clinicaltrials |
| NCT00080054 | A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | completed | Phase 1 | 24 | Pharmacyclics LLC.INDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00114309 | 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | unknown | Phase 2 | 66 | TransMolecularINDUSTRY | 1 | Apr 3, 2009 | clinicaltrials |
| NCT00115440 | BNCT to Treat Glioma That Has Progressed Following Radiotherapy | completed | Phase 1 / Phase 2 | 22 | Boneca CorporationINDUSTRY | 1 | Jan 28, 2009 | clinicaltrials |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 22, 2009 | clinicaltrials |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme | withdrawn | Phase 3 | 323 | Xenova BiomedixINDUSTRY | 2 | Jan 7, 2009 | clinicaltrials |
| NCT00306618 | Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma | completed | Phase 2 | 27 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Dec 10, 2008 | clinicaltrials |
| NCT00481455 | Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 2 | 15 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Nov 25, 2008 | clinicaltrials |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | terminated | Phase 1 / Phase 2 | 50 | Boneca CorporationINDUSTRY | 1 | Aug 18, 2008 | clinicaltrials |
| NCT00068952 | Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme | completed | Phase 3 | 118 | PfizerINDUSTRY | 13 | Apr 1, 2008 | clinicaltrials |
| NCT00001148 | Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor | completed | — | 25 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001171 | Evaluation of Factors in Human Brain Tumors | completed | — | 800 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00250887 | Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research | completed | Phase 2 | 22 | University of ZurichOTHER | 1 | Oct 23, 2007 | clinicaltrials |
| NCT00521482 | Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma | unknown | Phase 2 | 40 | University of ZurichOTHER | 1 | Aug 28, 2007 | clinicaltrials |
| NCT00394628 | AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 60 | NovaceaINDUSTRY | 1 | May 30, 2007 | clinicaltrials |
| NCT00430911 | Radiotherapy for Malignant Astrocytomas in the Elderly | completed | Phase 3 | — | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 2, 2007 | clinicaltrials |
| NCT00074646 | Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas | completed | Phase 1 | 36 | Celgene CorporationINDUSTRY | 1 | Jan 4, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2011source: clinicaltrials